The new laboratory will be located within the Milner Therapeutics Institute (MTI) on the Cambridge Biomedical Campus. It will be equipped with cutting-edge genomics technologies, including an advanced automated arrayed-CRISPR screening platform. This platform will enable researchers to rapidly identify and validate new drug targets.
The laboratory will also provide UK researchers with access to a wide range of other biological and technological tools, including:
- Next-generation sequencing (NGS)
- Single-cell RNA sequencing (scRNA-seq)
- Genome editing technologies
- High-throughput screening (HTS)
These tools will be used to identify and characterize new drug targets, develop new therapeutic strategies, and test the efficacy of new drugs.
The establishment of the new genomics laboratory is a significant milestone for Milner Therapeutics and its partners. It will provide researchers with the tools and resources they need to accelerate drug discovery and develop new treatments for a wide range of diseases.
Benefits of the New Genomics Laboratory
The new genomics laboratory is expected to have a number of benefits, including:
- Accelerated drug discovery: The laboratory will provide researchers with the tools and resources they need to rapidly identify and validate new drug targets. This could lead to the development of new drugs more quickly and efficiently.
- Improved drug efficacy: The laboratory will enable researchers to better understand the genetic basis of disease. This could lead to the development of more effective drugs.
- Reduced drug development costs: The laboratory could help to reduce the cost of drug development by identifying and validating new drug targets more quickly.
Impact on the UK's Genomics Leadership
The establishment of the new genomics laboratory is also expected to have a significant impact on the UK's genomics leadership. The laboratory will provide UK researchers with access to world-class genomics technologies and expertise. This could help to attract more international researchers to the UK and further strengthen the UK's position as a global leader in genomics research.
Quotes
"We are delighted to be partnering with AstraZeneca and the MRC to establish this new genomics laboratory," said Professor Sir Peter Donnelly, Director of the Milner Therapeutics Institute. "The laboratory will provide researchers with the tools and resources they need to accelerate drug discovery and develop new treatments for a wide range of diseases."
"This is an exciting development for the UK's genomics research community," said Sir John Bell, Chair of the Medical Research Council. "The new laboratory will help to ensure that the UK remains at the forefront of genomics research and that we continue to develop new treatments for patients."
"We are committed to supporting the development of new drugs for patients," said Sir Pascal Soriot, CEO of AstraZeneca. "The new genomics laboratory will provide our researchers with the tools and resources they need to accelerate drug discovery."
0 Comments